Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2024 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
November 30, 2023 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
August 17, 2023 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease

NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
May 25, 2023 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
May 17, 2023 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17

NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
April 20, 2023 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023

Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab...
April 04, 2023 10:43 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference

Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke)Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have...
March 28, 2023 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

First Phase 2 trial employing intranasal foralumab for treating inflammatory neurological diseaseTiziana received FDA Type C Meeting Minutes for proposed Phase 2 clinical trial in patients with...
March 17, 2023 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Highlighted in Forbes Article

NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
March 15, 2023 14:20 ET | Source: Straits Research

Monoclonal Antibodies Market Size is projected to reach USD 390.58 Billion by 2030, growing at a CAGR of 10.2%: Straits Research

New York, United States, March 15, 2023 (GLOBE NEWSWIRE) -- Antibodies that have been created in a lab by using a clone of a single B cell are called monoclonal antibodies (mAb). These antibodies...

Next Page keyboard_arrow_right